NASDAQ:ARQT Arcutis Biotherapeutics Q3 2025 Earnings Report $25.61 -0.58 (-2.21%) As of 08/17/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Arcutis Biotherapeutics EPS ResultsActual EPS$0.06Consensus EPS -$0.10Beat/MissBeat by +$0.16One Year Ago EPSN/AArcutis Biotherapeutics Revenue ResultsActual Revenue$99.22 millionExpected Revenue$86.69 millionBeat/MissBeat by +$12.53 millionYoY Revenue GrowthN/AArcutis Biotherapeutics Announcement DetailsQuarterQ3 2025Date10/28/2025TimeBefore Market OpensConference Call DateTuesday, October 28, 2025Conference Call Time9:30AM ETUpcoming EarningsArcutis Biotherapeutics' Q3 2026 earnings is estimated for Tuesday, October 27, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Arcutis Biotherapeutics Earnings HeadlinesArcutis (ARQT) Q2 2026 Earnings Call TranscriptAugust 13, 2026 | finance.yahoo.comHC Wainwright Has Positive Forecast for ARQT Q3 EarningsAugust 10, 2026 | americanbankingnews.comIran War: What Happened at 1:11 P.M. Outside D.C.?A source with ties to Saudi Arabia, the UAE, and the U.S. State Department revealed details of a potential 7 trillion dollar financial story unfolding behind the Iran conflict. Addison Wiggin, founder of the Grey Swan Investment Fraternity, investigated the claims himself and found enough corroboration to bring the story forward. The full account follows the money behind the headlines and shows why the Iran situation may look very different than reported. | Banyan Hill Publishing (Ad)Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $40.00August 9, 2026 | americanbankingnews.comWhat is HC Wainwright's Estimate for ARQT Q1 Earnings?August 9, 2026 | americanbankingnews.comArcutis Biotherapeutics (NASDAQ:ARQT) Raised to Strong-Buy at Wall Street ZenAugust 8, 2026 | americanbankingnews.comSee More Arcutis Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arcutis Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcutis Biotherapeutics and other key companies, straight to your email. Email Address About Arcutis BiotherapeuticsArcutis Biotherapeutics (NASDAQ:ARQT) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options. In August 2022, Arcutis received U.S. Food and Drug Administration approval for ZORYVE™ (roflumilast) cream, the company’s first commercial product, indicated for the treatment of plaque psoriasis in adults. Arcutis is also advancing a pipeline of next-generation roflumilast formulations, including topical ointments and foams, for the treatment of atopic dermatitis and seborrheic dermatitis. Additional clinical-stage programs include selective kinase inhibitors and other small-molecule assets aimed at expanding the company’s portfolio of dermatology therapies. Founded in 2017 and headquartered in Westlake Village, California, Arcutis has built a U.S. specialty commercial infrastructure to support the launch and market adoption of its products. The company is led by President and Chief Executive Officer Steven L. Gothel, whose leadership team brings extensive experience in dermatology drug development, regulatory affairs and commercial operations. Arcutis continues to collaborate with academic investigators and patient advocacy groups to advance its clinical programs and address unmet needs in dermatology.View Arcutis Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Birkenstock Beats the Skeptics—But Not on EPSThese 5 Dividend Stocks Show Why Income Investing Still MattersThe Quantum Race Is Heating Up—And 2 Small Players Stand OutMarketBeat Week in Review – 08/10 - 08/14Applied Materials Beat Everything but Wall Street’s Expectations for MarginsLooking Beyond CrowdStrike? 3 AI Security Stocks Stand Out5 Recession-Proof Stocks Hiding in Cardboard Boxes Upcoming Earnings Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026)Alibaba Group (8/20/2026)Ross Stores (8/20/2026)Walmart (8/20/2026)Deere & Company (8/20/2026)PDD (8/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
